Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - The data indicates that over 21% of company secretaries earn more than 1 million yuan annually [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries shows that 39% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 15% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age and Educational Background - The age distribution of company secretaries shows that 42% are between 40-50 years old, 29% are over 50, and 26% are under 40 [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are from Huaren Sanjiu, Jichuan Pharmaceutical, Tianshili, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries of 2.5587 million yuan, 2.4107 million yuan, 2.525 million yuan, 1.89 million yuan, and 1.3935 million yuan respectively [7] - The tenure of these top earners varies, with some having less than one year of service and others having up to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 59% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the most investor meetings are Zoli Pharmaceutical, Qizheng Tibetan Medicine, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with 410, 404, 298, 221, and 207 meetings respectively [9]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

Core Viewpoint - Kunming Pharmaceutical Group has been awarded the "Supply Chain Influence Award" for its outstanding practices in Environmental, Social, and Governance (ESG) areas, highlighting its commitment to integrating economic efficiency with social responsibility [1] Group 1: Environmental Practices - The company has established a systematic approach to environmental management, leveraging Yunnan's biodiversity with a GACP planting base covering 128,000 acres for traditional medicinal materials [4] - Kunming Pharmaceutical has implemented a heat recovery system at its manufacturing center, saving 3,200 tons of standard coal annually, and has reduced energy consumption per unit of output by 28.6% compared to 2020, with a wastewater reuse rate exceeding 65% [4] - The company collaborates with the Kunming Institute of Botany to cultivate endangered medicinal materials, maintaining a gene resource bank with over 1,200 species of medicinal plant seeds, ensuring sustainable resource utilization [4] Group 2: Supply Chain and Global Competitiveness - Kunming Pharmaceutical has developed a competitive international supply chain network, producing artemisinin and three derivatives, with three products included in the WHO's malaria treatment guidelines [4] - The company has built an SAP intelligent supply chain platform for visual management of procurement, production, and logistics, and established a blockchain-based traceability system for medicinal materials [5] Group 3: Social Responsibility - The company actively engages in various charitable activities, including disaster relief and educational support, contributing to social development and community building [5] - The "Sanqi Bank" model has increased the income of 246,000 farmers, with an average annual income increase of 12,000 yuan, positively impacting rural revitalization [5] - Employee welfare is prioritized, with an average training duration of 152 hours per R&D staff member in 2024 and a skill certification coverage rate of 98% for technical workers [5] Group 4: Future Outlook - Kunming Pharmaceutical aims to continue its commitment to sustainable development and optimize supply chain management to contribute to the high-quality development of the traditional Chinese medicine industry [6]

证券代码：600422 证券简称：昆药集团 公告编号：2025-039 号 昆药集团股份有限公司关于对外担保的进展公告 注：上述被担保人均为昆药集团股份有限公司（以下简称"本公司"、"公司" 或"昆药集团"）下属全资子公司昆药集团医药商业有限公司（以下简称"昆药商 业"）的控股子公司，不存在关联担保。 累计担保情况 对外担保逾期的累计金额（万元） 0 截至本公告日上市公司及其控股子 公司对外担保总额（万元） 45,615 对外担保总额占上市公司最近一期 经审计净资产的比例（%） 8.68 特别风险提示 □对外担保总额超过最近一期经审计净资产 100% □担保金额超过上市公司最近一期经审计净资产 50% □对合并报表外单位担保金额达到或超过最近一期经审 计净资产 30%的情况下 对资产负债率超过 70%的单位提供担保 其他风险提示 无 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 康桥"） 1,200 | 曲靖市康桥医药有限责任公司（以下简称"曲靖 | | --- ...

Core Points - The company announced a cash dividend of RMB 0.30 per share (before tax) for its shareholders [1] - The total cash dividend distribution amounts to RMB 227,092,727.10 based on a total share capital of 756,975,757 shares [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on June 20, 2025 [1] Distribution Details - The record date for the dividend is July 29, 2025, with the ex-dividend date and cash dividend payment date both set for July 30, 2025 [1][4] - Shareholders who are registered by the record date will receive the cash dividend through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - For individual shareholders and securities investment funds holding unrestricted circulating shares, the actual cash dividend after tax will be RMB 0.30 per share, with tax implications based on holding periods [3][5] Tax Implications - For individual shareholders, the tax rate varies based on the holding period: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [3] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in an actual cash dividend of RMB 0.27 per share [3][5] - Other institutional investors and corporate shareholders are responsible for their own tax payments, receiving the pre-tax dividend of RMB 0.30 per share [5]

Core Viewpoint - Kunming Pharmaceutical Group Co., Ltd. has received the drug registration certificate for Carbonate Sevelamer Dry Suspension, enhancing its product pipeline in the chronic kidney disease (CKD) management sector [1][2]. Drug Basic Information - The drug is named Carbonate Sevelamer Dry Suspension with a specification of 0.8g and is classified as a prescription chemical drug (Category 3) [1]. - The drug registration number is 国药准字 H20254872, and it is produced by Kunming Beikenuoton Pharmaceutical Co., Ltd. [1]. Drug Indications - The drug is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis and those with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis [2]. Market Context - Carbonate Sevelamer tablets were developed by Genzyme and approved in the U.S. in 2007, with the dry suspension form approved in the U.S. and EU in 2009 [2]. - In China, there are 10 approved manufacturers for Carbonate Sevelamer tablets, while only 3 for the dry suspension form, including the company [2]. - The domestic sales of Carbonate Sevelamer tablets are projected to be approximately 1.39 billion RMB in 2024 [2]. R&D Investment - The company has invested approximately 13.18 million RMB in the research and development of Carbonate Sevelamer Dry Suspension to date [3]. Strategic Impact - The approval of the drug registration certificate is expected to enhance the company's competitiveness in the chronic disease management market and contribute to its strategic focus on the aging health industry [3].

证券代码：600422 证券简称：昆药集团 公告编号：2025-038号 昆药集团股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"公司"）全资子公司昆明贝克诺顿制药有限公 司于近日收到国家药品监督管理局（以下简称"国家药监局"）核准签发的碳酸司维拉 姆干混悬剂《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 药品名称：碳酸司维拉姆干混悬剂 规格：0.8g 剂型：口服混悬剂 注册分类：化学药品 3 类 处方药/非处方药：处方药 截至本公告日，公司对碳酸司维拉姆干混悬剂累计研发投入约 1,318 万元人民币。 药品批准文号：国药准字 H20254872 上市许可持有人及生产企业：昆明贝克诺顿制药有限公司 申请事项：药品注册（境内生产） 审批结论：经审查，本品符合药品注册的有关要求，批准注册，发给药品注册证 书。质量标准、说明书、标签及生产工艺照所附执行。本品上市前需通过 GMP 符合 性检查。 适应症（或功能主治）：用于控制正在接受透析治疗的慢性肾 ...

证券代码：600422 证券简称：昆药集团 公告编号：2025-037 昆药集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.30元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/29 | － | 2025/7/30 | 2025/7/30 | 差异化分红送转： 否 3. 分配方案： 本次利润分配以方案实施前的公司总股本756,975,757股为基数，每股派发现金红利0.30 元（含税），共计派发现金红利227,092,727.10元。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/29 | － | 2025/7/30 | 2025 ...

Core Viewpoint - Kunming Pharmaceutical Group's subsidiary, Kunming Beikenuoton Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Sevelamer Carbonate Suspension, which is aimed at treating hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis and those not on dialysis with serum phosphorus levels ≥1.78mmol/L [1] Group 1 - The drug Sevelamer Carbonate Suspension is specifically designed for adult patients with chronic kidney disease [1] - The company has invested approximately 13.18 million RMB in the research and development of Sevelamer Carbonate Suspension [1]